Peapod Lane Capital’s NextCure NXTC Stock Holding History

Peapod Lane Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,120	Closed	-$127K	–	63
2025 Q1	$127K	Sell	22,120 -11,522	-34%	-$102K	0.14%	61
2024 Q4	$311K	Buy	+33,642	New	+$495K	0.31%	57

Other funds holding NXTC

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPA

Cardiff Park Advisors Carlsbad, California $1.25B AUM 24.12% 1-Year Est. Return

Peapod Lane Capital's NXTC Position: Q2 2025 in Review

Peapod Lane Capital sold out of NextCure (NXTC) in Q2 2025, closing a stake of 22,120 shares — an estimated $127K sold.

Peapod Lane Capital first reported a position in NXTC in Q4 2024 and held it in 2 quarters. The position peaked at $311K in Q4 2024. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2025.

Peapod Lane Capital reported no remaining NextCure position as of Q2 2025 after selling out during the quarter.
Peapod Lane Capital sold 22,120 NextCure shares in Q2 2025, an estimated $127K.
Peapod Lane Capital first reported a position in NextCure in Q4 2024 and held it in 2 quarters.
Peapod Lane Capital's NextCure position peaked at $311K in Q4 2024.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2025.

Based on Peapod Lane Capital's 13F filing for Q2 2025, filed 31 Jul 2025.